Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444256 · ClinicalTrials.gov registry record · Phase 2
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
A Phase 2 study of Stimulant Use Disorder, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06444256 is a Phase 2 study of Stimulant Use Disorder that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 208-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06444256, a Phase 2 study of Stimulant Use Disorder, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Conditions Studied
Interventions
- DRUG SUVO
- DRUG TAU
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06444256
The ClinicalTrials.gov registry entry for NCT06444256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (90% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stimulant Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which SUVO is the first listed.
NCT06444256 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06444256 about?
NCT06444256 is a clinical study titled "Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder". The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS)...
What is the current status of trial NCT06444256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-07-25. Estimated completion is 2027-01-30.
What conditions does trial NCT06444256 study?
This clinical trial studies the following conditions: Stimulant Use Disorder.
What interventions are being tested in trial NCT06444256?
The interventions under investigation include: SUVO (DRUG), TAU (DRUG).
Who is sponsoring clinical trial NCT06444256?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444256 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stimulant Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
RECRUITING · Phase 2
-
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
RECRUITING · NA
-
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
RECRUITING · NA
-
Smartphone Services for Stimulant Use Disorder
RECRUITING · NA
-
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
RECRUITING · Phase 1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.